LAVA Medtech Acquisition Corp.
LVACW
NASDAQ Global Market0.01
USD
+0.00
- -
CIK
0001855450
Return %
Stock
S&P500
1Y
- -
18.21
3Y
-97.92
64.38
5Y
-97.92
72.43
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- CIK
- 0001855450
- Similar Companies
- Business
- LAVA Medtech Acquisition Corp. is a special purpose acquisition company (SPAC) primarily engaged in facilitating mergers, capital stock exchanges, asset acquisitions, stock purchases, reorganizations, or similar business combinations focused on healthcare and biotechnology sectors, particularly targeting companies that offer innovative medical technologies and solutions. The company concentrates its business segments in medical technology, biotechnology, healthcare services, and digital health, including products such as advanced surgical instruments, diagnostic equipment, wearable health devices, implantable devices, biopharmaceuticals including gene therapies and monoclonal antibodies, virtual care platforms, patient management systems, and health informatics solutions like data analytics and remote patient monitoring tools. Founded as a SPAC in recent years, LAVA Medtech Acquisition Corp. is headquartered in Waltham, Massachusetts. In terms of latest major developments, the company has faced significant operational changes including a strategic restructuring plan in 2025 aimed at extending capital resources. This restructuring involved a workforce reduction of approximately 30% globally to better align with its focus on strategic alternatives and clinical development efforts, notably advancing a Phase 1 clinical trial for LAVA-1266 as a potential treatment for acute myeloid leukemia and myelodysplastic syndrome. The company discontinued its earlier asset LAVA-1207 after unsuccessful Phase 1 trials and closed operations in the Netherlands in 2024. It has also achieved key development milestones under partnerships with pharmaceutical companies Johnson & Johnson and Pfizer, receiving several million dollars in milestone payments related to clinical progress. These steps reflect LAVA's shift towards more focused clinical development and exploration of strategic alternatives in the medtech and biotech space. LAVA Medtech Acquisition Corp. operates by identifying and investing in promising healthcare and biotechnology companies, providing capital and strategic support to facilitate their growth primarily within the United States but with global operational activities including in Europe. The company’s engagements include research and development support, regulatory consulting, and assistance with clinical trials for new therapies and medical technologies. Its recent strategic emphasis on clinical programs like LAVA-1266 underlines its repositioning from broad acquisition ambitions to targeted clinical asset development and strategic partnerships within the medtech and biotech sectors. Overall, LAVA Medtech Acquisition Corp. is positioned as a medtech and biotech-focused SPAC that has transitioned towards direct clinical development and strategic evaluation following operational consolidations and asset pipeline refocus in the past two years. Its primary offerings span innovative medical devices, biopharmaceuticals, telehealth solutions, and health informatics with an ongoing commitment to developing advanced therapies and technologies through collaboration with major pharmaceutical partners and through internal clinical programs. This description integrates the company’s core business activities, product focus, recent restructuring and development efforts, and operational shifts reflecting its current strategic orientation as of 2025.